Advice

in the absence of a submission from the holder of the marketing authorisation:

chenodeoxycholic acid (Chenodeoxycholic acid Leadiant®) is not recommended for use within NHSScotland.

Indication under review: for the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis) in infants, children and adolescents aged 1 month to 18 years and adults.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice355KB (PDF)

Download

Medicine details

Medicine name:
chenodeoxycholic acid (Chenodeoxycholic acid Leadiant)
SMC ID:
SMC2190
Indication:
for the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis) in infants, children and adolescents aged 1 month to 18 years and adults.
Pharmaceutical company
Leadiant Biosciences
BNF chapter
Submission type
Non submission
Status
Not recommended
Date advice published:
13 May 2019